Back to results
US 12,551,489 B2Granted
Pharmaceutical compositions comprising meloxicam
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Estimating the term…
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A method of treating migraine, comprising orally administering one tablet to a human being experiencing a migraine attack, wherein the human being has 2 to 3 migraine attacks per month, wherein the tablet comprises about 20 mg of meloxicam, or a molar equivalent amount of a salt form of meloxicam, and from about 10 mg to about 15 mg of rizatriptan, or a molar equivalent amount of a salt form of rizatriptan, wherein the meloxicam is complexed with a sulfobutyl ether β-cyclodextrin (SBEBCD), wherein the human being does not have a cluster headache, wherein the Tmax of meloxicam in the human being is less than 60 minutes, and wherein the human being has acute pain.
A method of treating migraine, comprising orally administering one tablet to a human being experiencing a migraine attack, wherein the human being has 2 to 3 migraine attacks per month, wherein the tablet comprises about 20 mg of meloxicam, or a molar equivalent amount of a salt form of meloxicam, and from about 10 mg to about 15 mg of rizatriptan, or a molar equivalent amount of a salt form of rizatriptan, wherein the tablet further comprises sodium bicarbonate, wherein the human being does not have a cluster headache, wherein the Tmax of meloxicam in the human being is less than 60 minutes, and wherein the human being has acute pain.
A method of treating migraine, comprising orally administering one tablet to a human being experiencing a migraine attack, wherein the human being has 2 to 3 migraine attacks per month, wherein the tablet comprises 20 mg of meloxicam and 14.5 mg of rizatriptan benzoate, wherein the human being does not have a cluster headache, wherein the Tmax of meloxicam in the human being is less than 60 minutes, and wherein the human being has acute pain.
A method of treating migraine, comprising orally administering one tablet to a human being experiencing a migraine attack, wherein the human being has 2 to 3 migraine attacks per month, wherein the tablet comprises 20 mg of meloxicam and 14.5 mg of rizatriptan benzoate, wherein the tablet further comprises sodium bicarbonate, wherein the human being does not have a cluster headache, wherein the Tmax of meloxicam in the human being is less than 60 minutes, and wherein the human being has acute pain.
Dependencies are inferred from the claim text.